Acute Myeloid Leukemia News and Research

RSS

Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

Viewpoints: When a doctor should keep quiet; 2 views of hospital pricing; Stem cell 'snake oil'

In medical school, we were taught not to withhold information from our patients or to be "paternal" in making decisions for them. We internalized the idea that fully informed patients are better equipped to make treatment decisions.

17 May 2013

Novel cell sorting enhancement to MoFlo Astrios platform to be introduced by Beckman Coulter Life Sciences at CYTO 2013

Two seminars and seven poster sessions, Beckman Coulter will have a prominent role when CYTO 2013 convenes at the San Diego Convention Center May 18-22, 2013.

From Beckman Coulter Life Sciences - Flow Cytometry 16 May 2013

Secure cloud-based computing system to access, analyze human genomic cancer information

The University of Chicago launched the first secure cloud-based computing system that enables researchers to access and analyze human genomic cancer information without the costly and cumbersome infrastructure normally needed to download and store massive amounts of data.

16 May 2013

Researchers identify microRNA-155 as prognostic marker, treatment target in patients with AML

A study has identified microRNA-155 as a new independent prognostic marker and treatment target in patients with acute myeloid leukemia that has normal-looking chromosomes under the microscope (that is, cytogenetically normal acute myeloid leukemia, or CN-AML).

14 May 2013

Powerful data-sifting algorithms help untangle complex genetics of cancer

Powerful data-sifting algorithms developed by computer scientists at Brown University are helping to untangle the profoundly complex genetics of cancer.

2 May 2013

Genomics-based testing could change recommended course of treatment for endometrial cancer

The most in-depth look yet at endometrial cancer shows that adding genomics-based testing to the standard diagnostic workup could change the recommended course of treatment for some women.

2 May 2013

Research findings pave the way for developing better treatments for AML

A team of researchers led by Washington University School of Medicine in St. Louis has identified virtually all of the major mutations that drive acute myeloid leukemia, a fast-growing blood cancer in adults that often is difficult to treat.

2 May 2013

Findings set the stage for identifying potential new drug targets, treatment strategies for AML

nvestigators for The Cancer Genome Atlas Research Network have detailed and broadly classified the genomic alterations that frequently underlie the development of acute myeloid leukemia, a deadly cancer of the blood and bone marrow.

2 May 2013

Details about genomic landscapes of AML and endometrial cancer revealed

Two studies from The Cancer Genome Atlas program reveal details about the genomic landscapes of acute myeloid leukemia and endometrial cancer.

2 May 2013

Study identifies potential drug targets that interfere with cancer metabolism

A massive study analyzing gene expression data from 22 tumor types has identified multiple metabolic expression changes associated with cancer.

22 Apr 2013

BioLineRx gets regulatory approvals in US to start BL-8040 Phase IIa trial for treatment of AML

BioLineRx, a biopharmaceutical development company, announced today that it has received all necessary regulatory approvals in the US to commence a Phase IIa trial for BL-8040, for the treatment of Acute Myeloid Leukemia.

11 Apr 2013

MD Anderson professor to receive award for clinical research excellence at AACR meeting

Hagop Kantarjian, M.D., chair and professor in The University of Texas MD Anderson Cancer Center's Department of Leukemia, will be honored for clinical research excellence at the AACR Annual Meeting 2013, April 6-10.

9 Apr 2013

American Society of Hematology announces first recipients of ASH Bridge Grants

The American Society of Hematology, the world's largest professional organization dedicated to the causes and treatment of blood disorders, today announced the first recipients of the ASH Bridge Grants, a new award program designed to help hematologists continue their critical blood disease research amid severe funding reductions for the National Institutes of Health.

9 Apr 2013

Investigators examine effectiveness of probiotics for cancer treatment

One may not think of probiotics -- like those found in yogurt that promote good digestive health -- as a weapon used in the fight against cancer. But that is the focus of investigators at The Cancer Institute of New Jersey, who are examining the effectiveness of probiotics as they relate to the outcomes of bone marrow transplant for patients with blood cancers.

21 Mar 2013

Researchers complete phase II clinical trial of dasatinib for patients with higher-risk MDS

Researchers at Moffitt Cancer Center have completed a phase II clinical trial to determine the safety and efficacy of dasatinib for patients with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia resulting from MDS and have failed treatment with azanucleosides.

21 Mar 2013

Targeting Mer receptors sensitize AML and ALL to chemotherapies

Two University of Colorado Cancer Center studies show that the protein receptor Mer is overexpressed in many leukemias, and that inhibition of this Mer receptor results in the death of leukemia cells - without affecting surrounding, healthy cells.

12 Mar 2013

Stem cell transplantation could be delayed in acute myeloid leukemia

Stem cell transplantation could be delayed until a relapse occurs, without affecting overall survival, in some patients with acute myeloid leukemia, UK researchers report.

5 Mar 2013

Chroma Therapeutics, CTI announce results from tosedostat Phase 2 study on AML

Cell Therapeutics, Inc. (CTI) and Chroma Therapeutics Ltd. announced today that Lancet Oncology has published results from the OPAL Phase 2 study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML).

4 Mar 2013

Two antagonistic proteins help keep leukemia at bay

Two proteins that scientists once thought carried out the same functions are actually antagonists of each other, and keeping them in balance is key to preventing diseases such as cancer, according to new findings published in the February 25 issue of Developmental Cell by scientists at Fox Chase Cancer Center.

27 Feb 2013

Genetic variation in CD33 influences how AML patients' leukemic cell responds to GO

Researchers from the College of Pharmacy and Medical School working within the Masonic Cancer Center, University of Minnesota, have partnered to identify genetic variations that may help signal which acute myeloid leukemia (AML) patients will benefit or not benefit from one of the newest antileukemic agents.

26 Feb 2013

Acute Myeloid Leukemia News and Research

Further Reading

Viewpoints: When a doctor should keep quiet; 2 views of hospital pricing; Stem cell 'snake oil'

Novel cell sorting enhancement to MoFlo Astrios platform to be introduced by Beckman Coulter Life Sciences at CYTO 2013

Secure cloud-based computing system to access, analyze human genomic cancer information

Researchers identify microRNA-155 as prognostic marker, treatment target in patients with AML

Powerful data-sifting algorithms help untangle complex genetics of cancer

Genomics-based testing could change recommended course of treatment for endometrial cancer

Research findings pave the way for developing better treatments for AML

Findings set the stage for identifying potential new drug targets, treatment strategies for AML

Details about genomic landscapes of AML and endometrial cancer revealed

Study identifies potential drug targets that interfere with cancer metabolism

BioLineRx gets regulatory approvals in US to start BL-8040 Phase IIa trial for treatment of AML

MD Anderson professor to receive award for clinical research excellence at AACR meeting

American Society of Hematology announces first recipients of ASH Bridge Grants

Investigators examine effectiveness of probiotics for cancer treatment

Researchers complete phase II clinical trial of dasatinib for patients with higher-risk MDS

Targeting Mer receptors sensitize AML and ALL to chemotherapies

Stem cell transplantation could be delayed in acute myeloid leukemia

Chroma Therapeutics, CTI announce results from tosedostat Phase 2 study on AML

Two antagonistic proteins help keep leukemia at bay

Genetic variation in CD33 influences how AML patients' leukemic cell responds to GO

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

Latest News